No Data
No Data
Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models
Express News | Eterna: To Investigate Ability of Erna-101 to Induce, Modulate Antitumor Immunity in Ovarian Cancer, Breast Cancer Models Through Research
Eterna Therapeutics Launches Research to Evaluate Its Lead Induced Mesenchymal Stem Cell Therapy Candidate's (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Express News | Eterna Therapeutics Announces up to $1 Million Stock Repurchase Program
12 Health Care Stocks Moving In Monday's Pre-Market Session